Epic Bio
Epic Bio (legally Epicrispr Biotechnologies, Inc.) is a clinical-stage genetic medicines company in South San Francisco, California, founded in 2018 by Stanford CRISPR pioneer Stanley Qi, Ph.D. It develops epigenetic editing therapies that modulate gene expression without cutting DNA, built on its proprietary Gene Expression Modulation System (GEMS) platform — a combination of ultracompact DNA-binding proteins (CasMINI, CasONYX), tailored guide RNAs, and a large library of transcriptional and epigenomic modulators. Its lead program EPI-321 is in first-in-human clinical study for facioscapulohumeral muscular dystrophy (FSHD), with preclinical programs in alpha-1 antitrypsin deficiency and heterozygous familial hypercholesterolemia. The company is a therapeutics developer, not a software vendor: it publishes a corporate and scientific website but no developer program, public API, SDK, or machine-readable specification.
Epic Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genetic Medicine, Gene Editing, and CRISPR.
Epic Bio’s developer surface includes engineering blog, support, and 8 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Epic Bio Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 1
Properties that don't map to a standard resource type